公开(公告)号：US20210139912A1

公开(公告)日：2021-05-13

申请号：US16771907

申请日：2018-12-12

Applicant: AMGEN INC.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20220017906A1

公开(公告)日：2022-01-20

申请号：US17312721

申请日：2019-12-10

Applicant: Amgen Inc.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20250154512A1

公开(公告)日：2025-05-15

申请号：US19028462

申请日：2025-01-17

Applicant: AMGEN INC.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.